he company’s most advanced project PledOx® reduces serious side effects associated with chemotherapy. The drug candidate Aladote™ is developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 aims to limit the reperfusion damage to the heart muscle following a heart attack. PledPharma’s drug candidates are based on rational development of a pharmaceutical substance used for completely different purposes, which has already been used by more than 200,000 patients. This may limit the development risk and simplify the registration process.